- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.12. | Journey Medical Co. (NASDAQ:DERM) Sees Large Increase in Short Interest | 2 | MarketBeat | ||
| 13.11. | Journey Medical GAAP EPS of -$0.12 beats by $0.03, revenue of $14.63M beats by $0.24M | 1 | Seeking Alpha | ||
| 12.11. | Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights | 84 | GlobeNewswire (Europe) | U.S. FDA approved Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults; launch expected in late Q1 or early Q2 of 2025... ► Artikel lesen | |
| JOURNEY MEDICAL Aktie jetzt für 0€ handeln | |||||
| 12.11. | Journey Medical Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11. | FDA approves Journey Medical's Emrosi to treat inflammatory lesions of rosacea | - | PMLiVE | ||
| 05.11. | FDA approves Journey Medical's rosacea treatment Emrosi | 1 | Pharmaceutical Technology | ||
| 04.11. | Journey Medical, with FDA nod, won't stop believing it can establish new rosacea standard of care | 3 | FiercePharma | ||
| 04.11. | What's Going On With Journey Medical Stock Today? | 2 | Benzinga.com | ||
| 04.11. | Journey Medical: FDA Approves Emrosi For Treatment Of Inflammatory Lesions Of Rosacea | 1 | RTTNews | ||
| 04.11. | Journey Medical Corporation Announces U.S. FDA Approval of Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea | 128 | GlobeNewswire (Europe) | SCOTTSDALE, Ariz., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and... ► Artikel lesen | |
| 04.11. | Journey Medical Corp - 8-K, Current Report | - | SEC Filings | ||
| 03.10. | Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference | 2 | GlobeNewswire (USA) | ||
| 01.10. | PVG Asset Management Corp Purchases New Holdings in Journey Medical Co. (NASDAQ:DERM) | 2 | MarketBeat | ||
| 09.09. | Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference | 1 | GlobeNewswire (USA) | ||
| 06.09. | Lake Street starts Journey Medical with Buy, sets stock target on product launch | 1 | Investing.com | ||
| 04.09. | Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference | 2 | GlobeNewswire (USA) | ||
| 13.08. | Journey Medical Corporation (NASDAQ:DERM) Q2 2024 Earnings Call Transcript | 2 | Insider Monkey | ||
| 13.08. | Journey Medical holds steady with Buy rating on revenue beat | 2 | Investing.com | ||
| 13.08. | Earnings call: Journey Medical on track with solid Q2 results, DFD-29 launch | 2 | Investing.com | ||
| 12.08. | Journey Medical GAAP EPS of -$0.17 misses by $0.03, revenue of $14.85M beats by $0.97M | 1 | Seeking Alpha |
Seite:
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 25,400 | -1,07 % | Novo Nordisk speckt ab, Gerresheimer verliert ebenfalls an Wert, Eli Lilly frohlockt und auch bei Pfizer herrscht gute Laune | Noch vor Jahresende wollte Novo Nordisk neue Studiendaten zum in Entwicklung befindlichen Abnehmmedikament CagriSema vorstellen. Dieses Versprechen konnte das Unternehmen auch einlösen. Am Freitag erhielten... ► Artikel lesen | |
| GILEAD SCIENCES | 90,07 | +0,37 % | Gilead: Hohe Gewinnchance mit höchstem Risiko? | Der Ausbruch aus dem kurzfristigen Seitwärtstrend hat bisher nicht funktioniert aber das Chartbild sieht insgesamt optimistisch aus. Die Unterstützung wurde auf Schlusskursbasis nur für kurze Zeit durchbrochen... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 391,10 | +0,45 % | Vertex Pharmaceuticals Incorporated: Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13 | Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 7,352 | +5,72 % | EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 9,435 | 0,00 % | Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update | BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported... ► Artikel lesen | |
| ROCKET LAB USA | 27,200 | +10,57 % | Spotlight on Rocket Lab USA: Analyzing the Surge in Options Activity | ||
| OPKO HEALTH | 1,427 | 0,00 % | OPKO Health, Inc.: ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program | Brings total awards from BARDA to $110 million for development of broad SARS-CoV-2 and Influenza multispecifics, with potential funding of up to $205 million if all options are executedDevelopment... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 109,00 | -0,91 % | Ligand Pharmaceuticals (NASDAQ:LGND) Updates FY 2024 Earnings Guidance | ||
| JAZZ PHARMACEUTICALS | 119,25 | +0,34 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference | DUBLIN, Dec. 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 43rd Annual J.P. Morgan Healthcare... ► Artikel lesen | |
| ROYALTY PHARMA | 24,410 | +0,58 % | Royalty Pharma (NASDAQ:RPRX) Rating Increased to Strong-Buy at TD Cowen | ||
| TG THERAPEUTICS | 31,615 | +1,69 % | TG Therapeutics, Inc.: New Data for BRIUMVI (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment | During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained consistent... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 20,760 | +0,05 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE in Japan | CORAL GABLES, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing... ► Artikel lesen | |
| CATALENT | 59,93 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 18.12.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 18.12.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 18.12.2024ISIN NameJP3802670004 FANCL... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 12,900 | +1,57 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors | NORWOOD, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an oncology and obesity company with a diversified portfolio, today... ► Artikel lesen | |
| SOLIGENIX | 2,870 | 0,00 % | SOLIGENIX, INC.: Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma | FLASH2 Study opens patient enrollment PRINCETON, N.J., Dec. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company... ► Artikel lesen |
Das Unternehmen JOURNEY MEDICAL CORPORATION kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 4,370 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JOURNEY MEDICAL CORPORATION finden Sie auf Wallstreet Online.
